Introduction
============

Ventilator-associated pneumonia (VAP) is defined as nosocomial pneumonia that occurs in mechanically ventilated patients at least 48 h after the initiation of mechanical ventilation ([@B1]). Although the incidence of VAP varies according to the population and the different criteria used, VAP remains the leading cause of nosocomial infection in the intensive care unit ([@B8]). VAP has been associated with worsened patient outcomes, increased hospitalization cost and higher mortality rates ([@B22]). A number of evidence-based strategies have been used for the prevention and treatment of VAP ([@B6]; [@B15]). The primary treatment is the use of antimicrobial agents. With the increase of multidrug-resistant infections, it becomes more difficult to select appropriate antibiotics for patients with VAP ([@B22]). More efforts are needed to develop more effective prevention and treatment strategies.

Clinical trials are the most effective ways for evaluating preventive and therapeutic strategies ([@B10]; [@B19]). [ClinicalTrials.gov](https://clinicaltrials.gov) is a public trial registry provided by the U.S. National Library of Medicine and the U.S. Food and Drug Administration. In 2005, all International Committee of Medical Journal Editors (ICMJE) member journals released a statement that clinical trials must be publicly registered in trials' registries before they were considered for publication ([@B7]). [ClinicalTrials.gov](https://clinicaltrials.gov) registry which contains over 289,000 research studies conducted in 205 countries, is supposed to be the most comprehensive source for ongoing or completed clinical trials ([@B4]; [@B11]; [@B2]). Evaluating this registered clinical trials will enable us to gain a deeper understanding of drug control and prevention of VAP. In this study, we aimed to examine the characteristics of registered clinical trials regarding drug control and prevention of VAP.

Materials and Methods {#s1}
=====================

A cross-sectional, descriptive study of clinical trials on drug control and prevention of VAP which had been registered on the [ClinicalTrials.gov](https://clinicaltrials.gov) database was conducted. The trials were obtained from [ClinicalTrials.gov](https://clinicaltrials.gov) using the advanced search function with the search term "ventilator-associated pneumonia" for "condition" on August 25^th^, 2018. All of these searched clinical trials were gone through to identified records of all pharmaceutical trials. We extracted all the following information: registered number, study type, start date, the status of trial, study result, study sample, participant age, primary sponsor, location, primary purpose, the phases of trial, allocation, intervention model, masking and intervention. All trials were then further subclassified according to study type. We used descriptive statistics to characterize trial categories. Frequencies and percentages were provided for categorical data. Medians and interquartile ranges were used for continuous variables.

Results
=======

The initial search found 232 clinical trials registered on [ClinicalTrials.gov](https://clinicaltrials.gov) up to August 25^th^, 2018. After carefully reviewing all the information, 123 trials were excluded, including 10 trials not about VAP and 113 not pharmaceutical trials in patients with VAP). Thus, a total of 109 registered trials were included.

Basic Characteristics of Included Trials
----------------------------------------

Basic characteristics of the identified trials are shown in [Table 1](#T1){ref-type="table"}. Among the 109 eligible trials, 97 (89.0%) were interventional trials, and the 12 (11.0%) were observational trials. The trials were started from 1998 to 2018, with maximum studies started from 2012 to 2016. The status of more than half trials were completed (*n* = 59, 54.1%), followed by recruiting (*n* = 15, 13.8%). While 13 trials were terminated and 2 trials were withdrawn. Only 11.9% trials had results available, and 24.7% trials had web links for the publications of results on the [ClinicalTrials.gov](https://clinicaltrials.gov). Trials about VAP were mainly focused on adult patients, with 88.1% trials included only adult patients. Samples sizes were relatively large, with 62.9% trials enrolling 100 or more participants. The median number of participants per trial was 146 (66--270). Universities were listed as the primary sponsor for 40 (36.7%) trials, hospitals for 21 (19.3%) trials and industries for 31 (28.4%) trials. Of the 109 VAP trials, 37 (33.9%) trials were conducted in Europe, 36 (33.0%) in North America and 27 (24.8%) in Asia. 25.7% of trials were supported by industry funding.

###### 

Characteristics of included trials.

  Characteristics                                 Number   Percentage (%)
  --------------------- ------------------------- -------- ----------------
  Study type                                               
                        Interventional            97       89.0
                        Observational             12       11.0
  Year                                                     
                        Prior to 2006             23       21.1
                        2006--2009                20       18.3
                        2009--2012                15       13.8
                        2012--2016                31       28.4
                        2016--2018                20       18.3
  Status                                                   
                        Completed                 59       54.1
                        Recruiting                15       13.8
                        Active, not recruiting    1        0.9
                        Not yet recruiting        4        3.7
                        Enrolling by invitation   1        0.9
                        Withdrawn                 2        1.8
                        Terminated                13       11.9
                        Unknown status            14       12.8
  Study results                                            
                        No available results      96       88.1
                        Has available results     13       11.9
  Participant age (y)                                      
                        \<18                      7        6.4
                        \> = 18                   96       88.1
                        All                       6        5.5
  Enrollment                                               0.0
                        \< = 50                   24       22.0
                        50--100                   17       15.6
                        100--500                  52       48.1
                        \> = 500                  16       14.8
  Sponsor                                                  
                        University                40       36.7
                        Hospital                  21       19.3
                        Industry                  31       28.4
                        Other                     17       15.6
  Location                                                 
                        Europe                    37       33.9
                        North America             36       33.0
                        Asia                      27       24.8
                        South America             6        5.5
                        Oceanic                   2        1.8
                        Africa                    1        0.9
  Funded by                                                
                        Other                     62       56.9
                        Industry                  28       25.7
                        Other and Industry        15       13.8
                        Other and NIH             3        2.8
                        Other and U.S. Fed        1        0.9
                                                           

Characteristics of Study Design
-------------------------------

Study design characteristics of interventional trials are displayed in [Table 2](#T2){ref-type="table"}. Of the 97 interventional trials, 32 (33.0%) were phase 3 trials, 21 (21.6%) were phase 4 trials, and 16 (16.5%) were phase 2 trials. Primary purposes of interventional trials were the treatment (63.9%) and prevention (33.0%). Most trials were randomized trials with the parallel assignment. Among the 97 interventional trials, 41 (42.3%) trials were without masking, 21 (21.6%) with quadruple masking, 15 (15.5%) with double masking, 12 (12.4%) with triple masking and 9 (9.3%) with single masking. Study design characteristics of observational trials are shown in [Table 3](#T3){ref-type="table"}. Of the 12 interventional trials, 9 (75.0%) were cohort studies, and 1 (8.3%) was a case-only study. Ten (83.3%) trials were prospective and 2 (16.7%) were retrospective.

###### 

Study design elements of interventional trials.

  Characteristics                                Number   Percentage (%)
  -------------------- ------------------------- -------- ----------------
  Primary purpose                                         
                       Treatment                 62       63.9
                       Prevention                32       33.0
                       Other                     3        3.1
  Phases                                                  
                       Phase 1                   6        6.2
                       Phases 1/2                2        2.1
                       Phase 2                   16       16.5
                       Phases 2/3                6        6.2
                       Phase 3                   32       33.0
                       Phase 4                   21       21.6
                       Not applicable            14       14.4
  Allocation                                              
                       Randomized                88       90.7
                       Non-randomized            3        3.1
                       Missing value             6        6.2
  Intervention model                                      
                       Parallel assignment       83       85.6
                       Factorial assignment      2        2.1
                       Crossover assignment      3        3.1
                       Single group assignment   9        9.3
  Masking                                                 
                       Single                    9        9.3
                       Double                    15       15.5
                       Triple                    12       12.4
                       Quadruple                 21       21.6
                       None                      41       42.3
                                                          

###### 

Study design elements of observational trials.

  Characteristics                    Number   Percentage (%)
  ------------------ --------------- -------- ----------------
  Model                                       
                     Case-only       1        8.3
                     Cohort          9        75.0
                     Missing value   2        16.7
  Time perspective                            
                     Prospective     10       83.3
                     Retrospective   2        16.7
                                              

Overview of Investigated Drugs
------------------------------

A total of 32 trials investigated the drugs for the prevention of VAP, mainly focused on oral care, preemptive antibiotics and probiotics. A summary of studied drugs for prevention is provided in [Table 4](#T4){ref-type="table"}. Most of the trials investigated the effect of chlorhexidine (*n* = 13) for oral care. Nine trials investigated preemptive antibiotics, and five studies investigated the effect of probiotics in the prophylaxis of VAP. Sixty nine trials investigated the drugs for the treatment of VAP, mainly focused on antibiotics. An overview of drugs for the treatment of VAP is shown in [Table 5](#T5){ref-type="table"}. A total of 36 kinds of antibiotics were investigated for monotherapy or combination therapy. Beta-lactams were most studied, followed by aminoglycosides and polypeptides. Doripenem (*n* = 7), colistin (*n* = 7), and vancomycin (*n* = 6) were the three most investigated drugs. Thirteen trials investigated the effect of aerosolized antibiotics, including colistin, amikacin, ceftazidime, tobramycin, ancomycin, and gentamicin and five trials investigated the duration of antibiotic treatment. Other treatments involving oral care, stress ulcer prophylaxis and simvastatin therapy were also investigated.

###### 

Overview of drugs for prevention.

  Types        Name and number of investigated drug
  ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Oral care    Chlorhexidine (13)
               Potassium permanganate (1), Povidone iodine (1)
  Antibiotic   Amikacin (1), ASN100 (1), Azithromycin (1), Ceftriaxone (1), Colistin (1), KB001 (1), Iseganan hydrochloride (1), Sultamicillin (1), Neomycin/Colistin/Nystatin/Vancomycin (1)
  Others       *Lactobacillus* (5)
               Insulin (1), Atorvastatin (1), Pravastatin (1), Atropin (1)
               

###### 

Overview of drugs for treatment.

  Types                                       Name and number of investigated drug
  ------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic   Beta-lactams                   Doripenem (7)
                                              Ceftobiprole (4)
                                              Meropenem (3)
                                              Tazobactam (2)
                                              Imipenem (2)
                                              Piperacillin/Tazobactam (2)
                                              Ceftolozane/Tazobactam (2)
                                              Cefiderocol(S-649266)(2)
                                              Amoxicillin (1), Ceftazidime (1), Cefepime (1), Piperacillin (1), Cilastatin (1), Meropenem (1), Relebactam (MK-7655) (1), Amoxicillin/Clavulanate potassium (1), Aztreonam/Avibactam (1), Ceftazidime/Avibactam (1), Imipenem/Relebactam (1), Imipenem/Relebactam (1)
               Aminoglycosides                Amikacin (3)
                                              Gentamicin (2)
                                              Tobramycin (2)
               Polypeptides                   Colistin (7)
                                              Vancomycin (6)
                                              Murepavadin (POL7080) (2)
                                              Polymyxin B (1), Colimycin (1)
               Others                         Linezolid (5)
                                              Quinolone (1), Clarithromycin (1), Iclaprim (1), Metronidazole (1), Cotrimoxazole (1)
               Beta-lactams/aminoglycosides   Ceftazidime/Amikacin (1), Imipenem/Amikacin (1), Augmentin/Ceftriaxone/Cefotaxime/Netilmycin/Tobramycin (1)
               Beta-lactams/polypeptides      Imipenem/Cilastatin (3)
                                              Colistin/Imipenem (1), Polymyxin B/Doripenem (1)
               Beta-lactams/others            Linezolid/Ceftazidime (3)
               Others/others                  Linezolid/Vancomycin (1)
  Others                                      *Lactobacillus* (2)
                                              Chlorhexidine (1), Ranitidine (1), Sucralfate (1), Simvastatin (1), IC43 (1), KBPA-101 (1)
                                              

Discussion
==========

This study provides a descriptive assessment of trials registered on [ClinicalTrials.gov](https://clinicaltrials.gov) about drug control and prevention of VAP. We found the vast majority were interventional trials. More than half trials were completed, however, only 11.9% trials had available results. Relatively high percentage (13.7%) of trials were terminated or withdrawn. Most trials registered were relatively large samples, with the median number of 146 participants per trial. We demonstrated that interventional VAP trials were predominantly late-phase studies with a generally high proportion of randomized and parallel assignment studies. Drugs about oral care, preemptive antibiotics and probiotics were investigated for prevention. Drugs for treatment were mainly focused on antibiotics, with beta-lactams being most studied.

It is reassuring that most interventional studies were randomized (90.7%), parallel assigned (85.6%), and masked (57.7%). A further 21.6% of registered trials were quadruple masking. These values are higher than which have been reported among interventional clinical trials registered in the [ClinicalTrials.gov](https://clinicaltrials.gov) database during 2007 to 2010 ([@B4]). Randomization is regarded as a hallmark of a high-quality clinical trial ([@B16]). Randomization and blinding can reduce bias and make evidence more reliable. It is important for researchers to adopt randomization and blinding when feasible. Owing to the limited information on [ClinicalTrials.gov](https://clinicaltrials.gov), we could not judge whether all the trials were appropriately designed. Research in children are often regarded as challenging due to scientific, ethical and practical difficulties ([@B23]; [@B18]). All the interventional trials registered in [ClinicalTrials.gov](https://clinicaltrials.gov) from 2007 to 2010, only 17% trials included children ([@B4]). Trials about VAP were also mainly focused on adult patients, only 11.9% trials included children. More work is needed to ensure that children are involved in clinical trials of drugs so that more information could be provided for prescribing medications in children.

More than half trials were completed, however, only 11.9% trials had results available on the [ClinicalTrials.gov](https://clinicaltrials.gov), and 24.7% trials had web links for publications of results on the [ClinicalTrials.gov](https://clinicaltrials.gov). Similar non-publication rates of completed studies have been reported for clinical trials on the [ClinicalTrials.gov](https://clinicaltrials.gov) ([@B20]; [@B21]). Evidence indicates that positive trials were submitted more rapidly after completion and were published more rapidly after submission ([@B12]). Studies sponsored by pharmaceutical companies are unlikely to publish negative results or reports not favoring the funding entities ([@B14]; [@B3]). Consequently, there could be a potential for publication bias. The [ClinicalTrials.gov](https://clinicaltrials.gov) registry was created to make research more transparent and reduce publication bias. Publication of study results should be encouraged for all trials. Efforts should be made to let results of all completed studies available in the ClinicaTrials.gov registry in no delay. The percentage of terminated or withdrawn trials in our study was relatively high (13.7%). [@B4] found that the rate of interventional trials registered between 2007 and 2010 that was terminated or withdrawn trials was only 3.3% ([@B4]). We further explored and found that financial issues and lack of enrollment were the main reasons. Besides, one trial was stopped for futility after first scheduled analysis of recruitment of 300 participants ([@B17]). One trial was stopped after a scheduled review of data showing lower cure rates and higher mortality rates in one of the treatment groups ([@B13]).

Compared with trials for prevention, more trials were treatment-oriented, mainly focused on antibiotics. The right choice of the antimicrobial treatment is key to the prognosis of patients with VAP ([@B5]). The increase of multi-drug resistant organisms in HAP/VAP, especially gram-negative bacilli, make the selection of effective drugs more difficult ([@B9]). A total of 36 kinds of antibiotics were investigated for the treatment of VAP. However, most trials evaluated previously approved antibiotics, novel antimicrobial agents were less evaluated. Novel drugs for the treatment of VAP could improve the therapeutic options available and may offer a potential new opportunity to patients who have multi-drug resistant organisms. Thirteen studies investigated nebulized antibiotics for the treatment for VAP. Aerosolized antibiotics delivered through mechanical ventilation can achieve higher airway-drug concentrations with reduced systemic toxicity ([@B24]). There could be a place for nebulized antibiotics in VAP.

Our study had several limitations. First, [ClinicalTrials.gov](https://clinicaltrials.gov) does not include all clinical trials. However, as [ClinicalTrials.gov](https://clinicaltrials.gov) accounts for more than 80% of all studies in the World Health Organization's International Clinical Trials Registry Platform ([@B25]). So our analysis is broadly representative. Second, our study provides only an overview of the characteristics of the registered trials. The actual strengths and weaknesses of the clinical studies were not assessed. The validity of the data in [ClinicalTrials.gov](https://clinicaltrials.gov) is dependent on the quality of information provided by the sponsors. The missing data in some fields may introduce some bias into the results. Thirdly, we did not examine whether the registered trials have yet published the data in peer-reviewed journals. The proportion of trials that was published in the peer-reviewed literature requires further study.

The current study provides an overview of registered trials about drug control and prevention of VAP. It appears that most registered clinical trials are interventional trials with the purpose for treatment. Interventional trials tend to have a good trial design, with a relatively high proportion of randomized, blind and parallel assignment studies. Our analysis highlights the need for improvement in completeness of study results on the [ClinicalTrials.gov](https://clinicaltrials.gov).
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